Promoters
AssigneeBoehringer Ingelheim Vetmedica GmbH
InventorsAlice MUNDT, Andreas GALLEI, Ramesh KOUKUNTLA, Robert Barry MANDELL, Kristina REHMET, Eric Martin VAUGHN
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of (vector) vaccines, and especially to novel promoter sequences, expression cassettes and vectors, which are suitable to express genes of interest, especially antigen encoding sequences. The viral vectors of the present invention are useful for producing an immunogenic composition or vaccine.
Claims25
A promoter sequence comprising 4pgG600 (SEQ ID NO. 1) or 4pMCP600 (SEQ ID NO. 2) or the complementary nucleotide sequences thereof or a functional fragment thereof or the complementary nucleotide sequences thereof, wherein said promoter sequence leads to expression of a nucleotide sequence of interest, a gene of interest, and/or an antigen encoding sequence of interest.
An expression cassette comprising a promoter sequence selected from the group consisting of 4pgG600 (SEQ ID No. 1) and 4pMCP600 (SEQ ID No. 2) and the complementary nucleotide sequences thereof and a functional and the complementary nucleotide sequences thereof,
- wherein the promoter sequence is operably linked to a nucleotide sequence of interest, selected from the group consisting of:
- a gene of interest, a heterologous and/or exogenous sequence of interest, or an antigen encoding sequence of interest,
- wherein said promoter sequence leads to expression of the nucleotide sequence of interest,
- whereby said promoter sequence is a heterologous promoter sequence, and/or an exogenous promoter sequence.
A method of producing a vector, comprising
- a) providing a promoter sequence comprising 4pgG600 (SEQ ID NO. 1) or 4pMCP600 (SEQ ID NO. 2) or the complementary nucleotide sequences thereof or a functional fragment thereof or the complementary nucleotide sequences thereof, wherein said promoter sequence leads to expression of a nucleotide sequence of interest, and/or an antigen encoding sequence of interest,
- b) integrating said promoter sequence of step a) into a vector backbone derived from a virus, which is selected from the group consisting of:
- Herpesviridae, varicelloviruses, Adenoviridae (AdV), Parvoviridae like Adeno-associated viruses, Baculoviridae, Retroviridae, and Poxviridae.
An eukaryotic host cell line permissive to replication of a vector comprising a promoter sequence selected from the group consisting of 4pgG600 (SEQ ID No. 1) and 4pMCP600 (SEQ ID No. 2) and the complementary nucleotide sequences thereof and a functional and the complementary nucleotide sequences thereof,
- wherein the promoter sequence is operably linked to a nucleotide sequence of interest, selected from the group consisting of:
- a gene of interest, a heterologous and/or exogenous sequence of interest, or an antigen encoding sequence of interest,
- wherein said promoter sequence leads to expression of the nucleotide sequence of interest,
- whereby said promoter sequence is a heterologous promoter sequence, and/or an exogenous promoter sequence,
- wherein said host cell line is a mammalian cell line or an insect cell line, selected from the group consisting of:
- a PK/WRL cell line, a RK13 cell line, a MDBK cell line, a ST cell line, an AI-ST cell line, a VERO cell line, a Sf9 cell line, a Sf21, a Sf plus cell line, a MDCK cell line, and/or derivatives thereof.
A method of preparing a host cell, characterized by the following steps:
- a) infecting a permissive eukaryotic host cell line with a vector comprising a promoter sequence selected from the group consisting of 4pgG600 (SEQ ID No. 1) and 4pMCP600 (SEQ ID No. 2) and the complementary nucleotide sequences thereof and a functional and the complementary nucleotide sequences thereof,
- wherein the promoter sequence is operably linked to a nucleotide sequence of interest, selected from the group consisting of:
- a gene of interest, a heterologous and/or exogenous sequence of interest, or antigen encoding sequence of interest,
- wherein said promoter sequence leads to expression of the nucleotide sequence of interest, whereby said promoter sequence is a heterologous promoter sequence, and/or an exogenous promoter sequence,
- b) cultivating the infected cells of a) under suitable conditions, and
- c) optionally harvesting said host cell.
Use of a nucleic acid sequence comprising 4pgG600 (SEQ ID NO. 1) or 4pMCP600 (SEQ ID NO. 2) or the complementary nucleotide sequences thereof or a functional fragment thereof such as p430 (SEQ ID NO. 3) or p455 (SEQ ID NO. 4) or the complementary nucleotide sequences thereof, as a promotor sequence, wherein said nucleic acid sequence leads to expression of a nucleotide sequence of interest, a gene of interest, and/or an antigen encoding sequence.
A kit comprising
- a) a host cell(s),
- b) optionally a transfection reagent(s),
- c) an instruction leaflet, and
- d) a vector comprising a promoter sequence selected from the group consisting of 4pgG600 (SEQ ID No. 1) and 4pMCP600 (SEQ ID No. 2) and the complementary nucleotide sequences thereof and a functional and the complementary nucleotide sequences thereof,
- wherein the promoter sequence is operably linked to a nucleotide sequence of interest, selected from the group consisting of:
- a gene of interest, a heterologous and/or exogenous sequence of interest, or antigen encoding sequence of interest,
- wherein said promoter sequence leads to expression of the nucleotide sequence of interest,
- whereby said promoter sequence is a heterologous promoter sequence, and/or an exogenous promoter sequence.
Use of a vector for the manufacture of an immunogenic composition or vaccine, wherein said vector comprises a promoter sequence selected from the group consisting of 4pgG600 (SEQ ID No. 1) and 4pMCP600 (SEQ ID No. 2) and the complementary nucleotide sequences thereof and a functional and the complementary nucleotide sequences thereof,
- wherein the promoter sequence is operably linked to a nucleotide sequence of interest, selected from the group consisting of:
- a gene of interest, a heterologous and/or exogenous sequence of interest, or antigen encoding sequence of interest,
- wherein said promoter sequence leads to expression of the nucleotide sequence of interest,
- whereby said promoter sequence is a heterologous promoter sequence, and/or an exogenous promoter sequence.
An immunogenic composition comprising
- a) an expression cassette comprising a promoter sequence selected from the group consisting of 4pgG600 (SEQ ID No. 1) and 4pMCP600 (SEQ ID No. 2) and the complementary nucleotide sequences thereof and a functional and the complementary nucleotide sequences thereof,
- wherein the promoter sequence is operably linked to a nucleotide sequence of interest, selected from the group consisting of:
- a gene of interest, a heterologous and/or exogenous sequence of interest, or antigen encoding sequence of interest,
- wherein said promoter sequence leads to expression of the nucleotide sequence of interest,
- whereby said promoter sequence is a heterologous promoter sequence, and/or an exogenous promoter sequence, and/or
- b) a vector comprising the expression cassette of a), and/or
- c) a polypeptide expressed by the expression cassette of a) and/or a polypeptide expressed by the vector of b), and
- d) a pharmaceutical- or veterinary-acceptable carrier or excipient, wherein said carrier is suitable for oral, intradermal, intramuscular or intranasal application.
A vaccine or pharmaceutical composition comprising
- a) an expression cassette comprising a promoter sequence selected from the group consisting of 4pgG600 (SEQ ID No. 1) and 4pMCP600 (SEQ ID No. 2) and the complementary nucleotide sequences thereof and a functional and the complementary nucleotide sequences thereof,
- wherein the promoter sequence is operably linked to a nucleotide sequence of interest, selected from the group consisting of:
- a gene of interest, a heterologous and/or exogenous sequence of interest, or antigen encoding sequence of interest,
- wherein said promoter sequence leads to expression of the nucleotide sequence of interest,
- whereby said promoter sequence is a heterologous promoter sequence, and/or an exogenous promoter sequence, and/or
- b) a vector comprising the expression cassette of a), and/or
- c) a polypeptide expressed by the expression cassette of a) and/or a polypeptide expressed by the vector of b),
- d) a pharmaceutical- or veterinary-acceptable carrier or excipient suitable for oral, intradermal, intramuscular or intranasal application, and
- e) optionally an adjuvant.
A method for the preparation of an immunogenic composition or a vaccine for reducing the incidence or the severity of one or more clinical signs associated with or caused by an infection, comprising the following steps:
- a) infecting a permissive eukaryotic host cell line with a vector comprising a promoter sequence selected from the group consisting of 4pgG600 (SEQ ID No. 1) and 4pMCP600 (SEQ ID No. 2) and the complementary nucleotide sequences thereof and a functional and the complementary nucleotide sequences thereof,
- wherein the promoter sequence is operably linked to a nucleotide sequence of interest, selected from the group consisting of:
- a gene of interest, a heterologous and/or exogenous sequence of interest, or antigen encoding sequence of interest,
- wherein said promoter sequence leads to expression of the nucleotide sequence of interest,
- whereby said promoter sequence is a heterologous promoter sequence, and/or an exogenous promoter sequence,
- b) cultivating the infected cells of a) under suitable conditions,
- c) harvesting infected cells of b) and/or vector and/or virus components,
- d) optionally purifying the harvest of step c), and
- e) admixing said harvest with a pharmaceutically acceptable carrier.
A method of immunizing a food producing animal against a clinical disease caused by a pathogen in said food producing animal, said method comprising the step of administering to the animal the immunogenic composition comprising
- a) an expression cassette comprising a promoter sequence selected from the group consisting of 4pgG600 (SEQ ID No. 1) and 4pMCP600 (SEQ ID No. 2) and the complementary nucleotide sequences thereof and a functional and the complementary nucleotide sequences thereof,
- wherein the promoter sequence is operably linked to a nucleotide sequence of interest, selected from the group consisting of:
- a gene of interest, a heterologous and/or exogenous sequence of interest, or antigen encoding sequence of interest,
- wherein said promoter sequence leads to expression of the nucleotide sequence of interest,
- whereby said promoter sequence is a heterologous promoter sequence, and/or an exogenous promoter sequence, and/or
- b) a vector comprising the expression cassette of a), and/or
- c) a polypeptide expressed by the expression cassette of a) and/or a polypeptide expressed by the vector of b), and
- a pharmaceutical- or veterinary-acceptable carrier or excipient, wherein said carrier is suitable for oral, intradermal, intramuscular or intranasal application,
- whereby said immunogenic composition fails to cause clinical signs of infection but is capable of inducing an immune response that immunizes the food producing animal against pathogenic forms of said pathogen.
A kit for vaccinating a food producing animal against a disease associated with and/or reducing the incidence or the severity of one or more clinical signs associated with or caused by a pathogen in an animal comprising
- a) a dispenser capable of administering an immunogenic composition to said animal;
- and
- b) an immunogenic comprising:
- i) an expression cassette, and/or
- ii) a vector, and/or
- iii) a polypeptide expressed by the expression cassette of i) and/or a polypeptide expressed by the vector of ii),
- wherein said expression cassette of i) and/or the vector of ii) comprises a promoter sequence selected from the group consisting of 4pgG600 (SEQ ID No. 1) and 4pMCP600 (SEQ ID No. 2) and the complementary nucleotide sequences thereof and a functional and the complementary nucleotide sequences thereof,
- wherein the promoter sequence is operably linked to a nucleotide sequence of interest, selected from the group consisting of:
- a gene of interest, a heterologous and/or exogenous sequence of interest, or antigen encoding sequence of interest,
- wherein said promoter sequence leads to expression of the nucleotide sequence of interest,
- whereby said promoter sequence is a heterologous promoter sequence, and/or an exogenous promoter sequence,
- iv) a pharmaceutical- or veterinary-acceptable carrier or excipient, wherein said carrier is suitable for oral, intradermal, intramuscular or intranasal application, and
- c) optionally an instruction leaflet.
Dependencies are inferred from the claim text.